ArticlePediatric nephrology (Berlin, Germany)2018
Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
Article in Pediatric nephrology (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review.Clinical rheumatology · 2024Pooled it
- Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force.Annals of the rheumatic diseases · 2023Pooled it
- Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.BioMed research international · 2019Pooled it
- Paediatric lupus nephritis: defining remission and the evolving therapeutic landscape.Pediatric nephrology (Berlin, Germany) · 2026Article
- Clinical presentations, treatments, and outcomes of pediatric lupus nephritis: a prospective cohort study from the Pediatric Nephrology Research Consortium.Pediatric nephrology (Berlin, Germany) · 2026Article
- Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.Pediatric nephrology (Berlin, Germany) · 2026Review
- Expert collaborative evidence-based consensus for childhood lupus nephritis diagnosis and treatment: unifying clinical approach in Saudi Arabia.Pediatric rheumatology online journal · 2026Article
- Hyperoside Attenuates Lupus Nephritis-Associated Mesangial Cell Apoptosis via the P53/XAF1 Pathway: Integrative Bioinformatics and In Vitro Validation.Journal of inflammation research · 2026Article
- The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan.Pediatric nephrology (Berlin, Germany) · 2025Review
- CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?Arthritis research & therapy · 2025Review
- New Insights on Childhood Lupus Nephritis.International journal of nephrology and renovascular disease · 2025Review
- Managing Lupus Nephritis in Children and Adolescents.Paediatric drugs · 2024Review
- Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis.Frontiers in medicine · 2024Review
- Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2023Article
- Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.Pediatric rheumatology online journal · 2021Article
- Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2021Article
- Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study.Pediatric nephrology (Berlin, Germany) · 2020Article
- Clinical efficacy and safety of rituximab in lupus nephritis.Drug design, development and therapy · 2019Article
- Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis.International journal of pediatrics & adolescent medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn clinical trials, the addition of rituximab (RTX) to the combination therapeutic regimen of mycophenolate mofetil (MMF) and corticosteroids failed to improve outcome in lupus nephritis (LN). However, recent data suggest that RTX may have steroid-sparing beneficial effects with an efficacy similar to that of conventional regimens. We report our experience with RTX in the treatment of children with LN.
methodsPatients treated with RTX for first occurrence of LN class III to V were enrolled in the study. Treatment consisted of methylprednisolone pulse (500 mg/m
resultsTwelve patients were included in the study, with median follow-up of 23.7 [interquartile range (IQR) 12.8-33.5] months. Median age of the patients was 13.6 [12.3-15.1] years, median proteinuria was 32 [19-67] mg/mg and median estimated glomerular filtration rate was 76.1 [59.3-97.7] mL/min/1.73 m
conclusionsIn our pediatric patients with LN, therapy with RTX + MMF combined with a rapid decrease in steroid appears to have been an efficacious treatment for severe LN but was associated with high rate of VZV infection. The potential of RTX to allow complete steroid avoidance warrants further investigation in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.